Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on March 30, 2022. The company is a Nevada corporation with principal executive offices in La Jolla, California, and its common stock trades on The NASDAQ Stock Market LLC under the symbol "INMB." The report identifies the company as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain financial statements or performance metrics.
Material Changes
There are no material financial changes reported in this filing. The document discloses a corporate event regarding the company's scientific leadership and upcoming industry presentation.
Guidance, Outlook, and Management Commentary
Item 8.01 (Other Events) announces that the Company's Chief Scientific Officer, Dr. Lowdell, will lead a workshop titled "Challenges of NK Immunotherapy of Solid Tumors: Potentiation of intra-tumoral NK Function." This presentation is part of the 7th Innate Killer Summit held in San Diego from March 30 to April 1, 2022. The filing includes a press release as Exhibit 99.1 detailing this event. No financial guidance or risk factors specific to this event are disclosed in the text.
Important Facts for Investors to Verify
- Verify the content of the press release attached as Exhibit 99.1 for details on the scientific workshop.
- Confirm the company's status as an emerging growth company and any associated reporting exemptions.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial performance.